⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030
globenewswire.com
PFE
MRK
IDYA
BMY
MDT
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
prnewswire.com
IDYA
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
prnewswire.com
IDYA
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
prnewswire.com
IDYA
Incode behaalt als eerste het hoogste niveau van onafhankelijke identiteitsbeveiligingstests van iBeta op zowel iOS als Android met een foutpercentage van 0%
businesswire.com
IDYA
百奧賽圖宣布達成重要臨床里程碑，合作夥伴IDEAYA啟動雙抗ADC IDE034第一期臨床試驗並完成首例病患給藥
businesswire.com
IDYA
百奧賽圖宣布達成重要臨床里程碑，合作夥伴IDEAYA啟動雙抗ADC IDE034第一期臨床試驗並完成首例病患給藥
businesswire.com
IDYA
バイオサイトジェン、IDEAYAのファーストインクラスB7H3/PTK7二重特異性TOP1 ADC「IDE034」第1相試験で初の患者への投与、臨床マイルストーン達成
businesswire.com
IDYA
Biocytogen annuncia un importante traguardo clinico – trattato il primo paziente nel trial di fase 1 di IDE034, l’ADC TOP1 bispecifico per B7H3/PTK7 “first-in-class” sviluppato da IDEAYA
businesswire.com
IDYA